Meridian Bioscience Pulls Out Revogene COVID-19 Test EUA Application

by Vandana Singh, Benzinga Editor

February 23, 2021 9:33 AM | 1 min read | Make a Comment

After submitting a written response to the FDA's request for additional information on Meridian Bioscience Inc's (NASDAQ: VIVO) Revogene SARS-CoV-2 test on February 16 and further discussions with the FDA, the company decided to withdraw its Emergency Use Authorization (EUA) application.
The company plans to conduct a new clinical validation study and a Limit-of-Detection bridging study, with potential re-submission of a EUA application during Q3 of 2021.
Price Action: VIVO is down 3.39% at $22.23 on the last check Tuesday.

Posted In: News Health Care Small Cap FDA General COVID-19 Testing

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.